RxDoctor Payments Data

Joseph Myers, MD

Urology · Clinton, MONPI 1598731242

Payments from drug & device makers

$1,688in general payments, 2019–2025

Across 29 payments — averaging $58.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$207
  • Boston Scientific$40
  • Immunitybio, Inc.$21
  • Amgen$18
  • Organon$17
  • plus $70 from 5 others

What the payments were for

  • Travel & lodging$1,01660%
  • Food & beverage$58234%
  • Education$905%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Procept Biorobotics Corporation8$1,314
Astellas Pharma US Inc11$207
Boston Scientific2$40
Immunitybio, Inc.1$21
Amgen1$18
Organon1$17
Dexcom, Inc.1$16
Bayer1$15
Otsuka America Pharmaceutical, Inc.1$15
180 Medical, Inc.1$12
Johnson & Johnson1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,688 in reported general payments places this provider in the 30th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$71,635
Medicare patients
506
Services billed
883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron422$241,026
GemtesaVibegron203$150,423
Methenamine Hippurate429$17,139
Tamsulosin Hcl1,095$13,468
Oxybutynin Chloride ErOxybutynin Chloride652$9,019
Desmopressin Acetate109$7,449
Finasteride645$6,727
Tolterodine Tartrate ErTolterodine Tartrate114$6,465
Imipramine Hcl196$4,768
Mirabegron ErMirabegron11$4,701
Bicalutamide151$3,921
Fesoterodine Fumarate ErFesoterodine Fumarate39$2,602
Solifenacin Succinate115$2,546
Potassium Citrate ErPotassium Citrate16$2,207
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst74$2,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$207$241,026422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 250 urology providers in Missouri.

Other urology in Clinton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →